Related Experiment Video
Updated: Dec 9, 2025
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
6.2K
Midterm Results for Robotic Thymectomy for Malignant Disease
Travis C Geraci1, Dana Ferrari-Light2, Natalie Pozzi3
1Department of Cardiothoracic Surgery, New York University Langone Health, New York, New York.
The Annals of Thoracic Surgery
|September 14, 2020
Summary
Robotic thymectomy for malignant disease is safe and effective, achieving high rates of complete tumor removal. Midterm follow-up shows low recurrence for thymoma, but longer studies are needed for full oncologic assessment.
Area of Science:
- Thoracic surgery
- Surgical oncology
- Robotic surgery
Background:
- Limited data exists on robotic thymectomy for malignant conditions.
- This study reviews single-center experience and outcomes for robotic thymectomy in cancer patients.
Purpose of the Study:
- To evaluate the safety and efficacy of robotic thymectomy for malignant disease.
- To assess midterm oncologic outcomes and perioperative results.
Main Methods:
- Prospective database review of patients undergoing robotic resection for malignancy (Jan 2010 - Jun 2019).
- Analysis of 84 patients who underwent robotic thymectomy for malignant disease, with a focus on thymoma.
Main Results:
- High complete resection rate (R0) of 98.8% achieved, even for larger tumors (median 4.7 cm).
- Excellent perioperative outcomes: median operative time 81.5 min, median length of stay 1 day, low morbidity (3.5%), and no 30/90-day mortality.
- For thymoma patients (n=57), median follow-up was 32 months with a low ipsilateral chest recurrence rate (1.8%).
Conclusions:
- Robotic thymectomy is a safe procedure for malignant disease, offering excellent perioperative results.
- The robotic approach facilitates high rates of complete tumor resection.
- While midterm recurrence rates for thymoma are low, long-term oncologic durability requires further investigation.
